Scilex Holding Co
Scilex Holding Co is a U.S.-based biopharmaceutical company focused on non-opioid pain management and other specialty pharmaceutical products. Its commercial portfolio includes ZTlido, ELYXYB, and GLOPERBA, and it also develops product candidates such as SP-103, SP-104, and SEMDEXA through its operating subsidiaries and related collaborations.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaApproved pharmaceutical products sold in the U.S., including ZTlido, ELYXYB and GLOPERBA.
Development-stage programs for pain and related therapeutic areas, including SP-103, SP-104 and SEMDEXA.
Rights, royalties and supply arrangements tied to product commercialization and manufacturing partners.
Asiakkaat
Scilex sells primarily into the U.S. pharmaceutical channel, where prescription products are purchased through wholesalers, pharmacies, and other distribution intermediaries before reaching patients. Demand is driven by physicians, payors, and patients in pain management and migraine care, while GLOPERBA serves a specialty colchicine market. The company also relies on manufacturing and development partners for supply and commercialization support.
Wholesalers, regional distributors and pharmacies that buy and distribute ZTlido, ELYXYB and GLOPERBA.
Clinicians who prescribe the company's branded therapies for pain, migraine and related indications.
Commercial and government reimbursement decision-makers that affect access, rebates and net sales.
End users of the company's prescription products, especially in non-opioid pain and migraine care.
Counterparties in licensing, supply and joint venture arrangements that support pipeline development.
Strategia
Scilex is focused on expanding commercial awareness and utilization of its marketed products while advancing its pain and neurology pipeline. The company also uses partnerships, licensing and financing transactions to support development programs and maintain flexibility across commercialization and R&D. Its strategy depends on building prescription demand for current products while progressing product candidates toward regulatory milestones.
Current revenue depends on prescription uptake and channel access for ZTlido, ELYXYB and GLOPERBA.
Future value depends on clinical and regulatory progress for product candidates in pain and related indications.
The business model requires external capital and collaboration to support commercialization and R&D.
Maantiede
Scilex is primarily a United States business, with net revenue from product sales of ZTlido, ELYXYB and GLOPERBA generated in the U.S. The company also has product and royalty arrangements tied to Canada and foreign suppliers, which create some cross-border operating exposure even though commercialization is centered in the U.S. Its development and supply chain depends on third-party manufacturers and partners outside the U.S., including Japanese suppliers for lidocaine tape products.
Riskit
Scilex faces the typical risks of a specialty biopharmaceutical company: dependence on a small number of products, uncertain prescription demand, reimbursement pressure and clinical development risk. It also has meaningful financing, supply chain and foreign exchange exposure because it relies on third-party manufacturers, royalty arrangements and external capital to support operations and pipeline development.
- Dependence on a small commercial portfolioVaikutus: KorkeaTodennäköisyys: Korkea
Revenue is concentrated in a few branded products, so any slowdown in prescription demand or access can materially affect results.
Kohdistuu - Financing and going-concern riskVaikutus: KorkeaTodennäköisyys: Korkea
The company expects to need additional capital to fund operations and development, which can dilute shareholders or constrain execution.
Kohdistuu - Clinical and regulatory development riskVaikutus: KorkeaTodennäköisyys: Korkea
Pipeline assets may not demonstrate efficacy, safety or approvability, which would limit future growth options.
Kohdistuu - Supply chain and single-source dependencyVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Commercial supply and clinical materials are obtained from third-party and sometimes sole-source manufacturers, creating disruption risk.
Kohdistuu - Reimbursement and gross-to-net pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Rebates, chargebacks, returns and discounts reduce realized revenue and can vary with payer mix and channel dynamics.
Kohdistuu: Government and commercial payors
Kirjanpito
Harkinnanvaraiset erätNet sales depend on rebates, chargebacks, returns and discounts, which can create quarter-to-quarter volatility.
Vaikutus: Affects reported revenue and receivables
ZTlido and ELYXYB arrangements require ongoing royalty payments that must be accrued and expensed appropriately.
Vaikutus: Affects cost of revenue and current liabilities
Perishable pharmaceutical inventory can require write-downs for expiration or excess stock.
Vaikutus: Affects gross margin and operating results
Convertible notes, warrants, deferred consideration and JV-related instruments may require complex valuation inputs.
Vaikutus: Affects non-cash gains/losses and balance sheet values
Acquired product rights and development assets must be assessed for recoverability and impairment.
Vaikutus: Affects asset values and future expense recognition
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Semnur Pharmaceuticals, Inc.
SMNR · Pharmaceutical Preparations
Lexicon Pharmaceuticals, Inc
LXRX · Pharmaceutical Preparations
Lexicon Pharmaceuticals is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing small-molecule medicines.
Addex Therapeutics Ltd.
ADXN · Pharmaceutical Preparations
Tonix Pharmaceuticals Holding Corp.
TNXP · Pharmaceutical Preparations
NRX Pharmaceuticals, Inc.
NRXP · Pharmaceutical Preparations
BioLineRx Ltd.
BLRX · Pharmaceutical Preparations
Päivitetty: 24.9.2026